She is currently accumulating Medicare-specific data for EGFR testing, which, along with the Genzyme data, should give a complete picture. The federal health program began reimbursing EGFR testing in 2009.
Ms. Lynch ruled out reimbursement issues and technological constraints as factors in underuse of the tests, but acknowledged that even with Medicare coverage, it could be an expensive proposition for a beneficiary, as they have a 20% copay. The test costs $600-$800, she said.
EGFR testing needs to be more widespread, said Ms. Lynch, noting that not only does it help patients get the best treatment, but that it also provides crucial data for the development of new therapies.
The study was funded by grants from the U.S. Department of Education and the National Institutes of Health, and was aided by the provision of data by Genzyme Genetics. Ms. Lynch is a former employee of Genentech Corp.